Adamas Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 21.972 million compared to USD 18.794 million a year ago. Operating loss was USD 9.155 million compared to USD 7.314 million a year ago. Net loss was USD 12.344 million compared to USD 10.566 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.37 a year ago. For the half year, total revenue was USD 41.283 million compared to USD 33.275 million a year ago. Operating loss was USD 18.680 million compared to USD 20.422 million a year ago. Net loss was USD 24.917 million compared to USD 27.214 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.97 a year ago.